L. Wolf

Effects of Empagliflozin on Progression of Chronic Kidney Disease: A Pre-Specified Secondary Analysis from the Empa-Kidney Trial

M. Seman, T. Miyatsuka, Y. Lee-Barkey, 2023, The lancet. Diabetes & endocrinology.

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

M. Seman, T. Miyatsuka, Y. Lee-Barkey, 2023, The lancet. Diabetes & endocrinology.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

N. Perico, M. Jardine, V. Perkovic, 2023, The Lancet.